Dr. Denburg addresses fundamental limitations in understanding of skeletal morbidity in patients with chronic kidney disease, glomerular disease, and urinary stone disease, and develops resources to conduct observational research and trials to optimize health outcomes in these high risk populations.
Dr. Hartung's clinical and translational research program focuses on autosomal recessive polycystic kidney disease and other genetic kidney diseases, development of new kidney and liver imaging biomarkers, and neurocognitive outcomes in children with chronic kidney disease.
Dr. Levy-Erez's research is focused on the discovery of immune urinary biomarkers among children developing acute kidney injury. She is studying both a unique population of immune-compromised children after hematopoietic stem cell transplantation (HSCT) as well as children who have an intact immune system who develop acute kidney injury after cardiac bypass surgery.
Dr. Amaral's research is focused on kidney transplantation with particular interests in reducing treatment burden for adolescents and young adults — from designing studies to make daily medication regimens easier to diagnosing transplant injury earlier using innovative, noninvasive approaches.
Dr. Pradhan is chief of the Division of Nephrology and outpatient director of the Dialysis Unit at Children's Hospital of Philadelphia, and professor of Clinical Pediatrics in the Perelman School of Medicine at the University of Pennsylvania. Her research focuses on neuroimaging in chronic kidney disease.
Dr. Furth's research focuses on defining risk factors for kidney disease progression in children; characterizing the effect of kidney function decline on neurodevelopment, cognitive abilities and behavior; identifying the prevalence and evolution of cardiovascular disease risk factors, and examining the effects of declining glomerular filtration rate on children’s growth.
Dr. Laskin's research focuses on the conduct of clinical investigations and translational studies designed to target mechanisms to prevent, treat, or slow the progression of chronic kidney disease in immunosuppressed patients, including children receiving a bone marrow or kidney transplant.